CoChat
Sign Up
Cited by 70Mesenchymal stem cell researchCancer Cells and MetastasisSarcoma Diagnosis and Treatment

New perspective into mesenchymal stem cells: Molecular mechanisms regulating osteosarcoma

Open access
Chang, Xingyu, Ma, Zhanjun, Zhu, Guomao, Lu, Yubao, Yang, Jingjing·2021·Journal of Bone Oncology
DOI 10.1016/j.jbo.2021.100372PMC PMC8254115
Open this paper in CoChat — free accountOpen PDF

Abstract

Mesenchymal stem cells (MSCs) are multipotent stem cells with significant potential for regenerative medicine. The tumorigenesis of osteosarcoma is an intricate system and MSCs act as an indispensable part of this, interacting with the tumor microenvironment (TME) during the process. MSCs link to cells by acting on each component in the TME via autocrine or paracrine extracellular vesicles for cellular communication. Because of their unique characteristics, MSCs can be modified and processed into good biological carriers, loaded with drugs, and transfected with anticancer genes for the targeted treatment of osteosarcoma. Previous high-quality reviews have described the biological characteristics of MSCs; this review will discuss the effects of MSCs on the components of the TME and cellular communication and the prospects for clinical applications of MSCs.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.jbo.2021.100372

Cites

9 of 9 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Osteosarcoma may arise from mesenchymal stem cells (MSCs), which contribute to modulate immune responses, facilitate cell fusion and differentiation.

    “Extensive research suggests that osteosarcoma may arise from mesenchymal stem cells (MSCs), which contribute to modulate immune responses, facilitate cell fusion and differentiation [45].”

    From Advances on immunotherapy for osteosarcoma (2024) · cites this paper as [45]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 107

  1. [1]Main H. Munsie M. O’Connor M.D. Managing the potential and pitfalls during clinical translation of emerging stem cell therapies Clin. Transl. Med. 3 2014 10 10.1186/2001-1326-3-10 24949190 PMC4049443 · DOI
  2. [2]Kawai T. Katagiri W. Osugi M. Sugimura Y. Hibi H. Ueda M. Secretomes from bone marrow-derived mesenchymal stromal cells enhance periodontal tissue regeneration Cytotherapy. 17 2015 369 381 10.1016/j.jcyt.2014.11.009 25595330 · DOI
  3. [3]Kim H.K. Lee S.G. Lee S.W. Oh B.J. Kim J.H. Kim J.A. Lee G. Jang J.D. Joe Y.A. A subset of paracrine factors as efficient biomarkers for predicting vascular regenerative efficacy of mesenchymal stromal/stem cells Stem Cells. 37 2019 77 88 10.1002/stem.2920 30281870 · DOI
  4. [4]Rüster B. Göttig S. Ludwig R.J. Bistrian R. Müller S. Seifried E. Gille J. Henschler R. Mesenchymal stem cells display coordinated rolling and adhesion behavior on endothelial cells Blood. 108 2006 3938 3944 10.1182/blood-2006-05-025098 16896152 · DOI
  5. [5]Ortiz L.A. Gambelli F. McBride C. Gaupp D. Baddoo M. Kaminski N. Phinney D.G. Mesenchymal stem cell engraftment in lung is enhanced in response to bleomycin exposure and ameliorates its fibrotic effects Proc. Natl. Acad. Sci. U.S.A. 100 2003 8407 8411 10.1073/pnas.1432929100 12815096 PMC166242 · DOI
  6. [6]Sato Y. Araki H. Kato J. Nakamura K. Kawano Y. Kobune M. Sato T. Miyanishi K. Takayama T. Takahashi M. Takimoto R. Iyama S. Matsunaga T. Ohtani S. Matsuura A. Hamada H. Niitsu Y. Human mesenchymal stem cells xenografted directly to rat liver are differentiated into human hepatocytes without fusion Blood. 106 2005 756 763 10.1182/blood-2005-02-0572 15817682 · DOI · Paper page
  7. [7]Ji J.F. He B.P. Dheen S.T. Tay S.S. Interactions of chemokines and chemokine receptors mediate the migration of mesenchymal stem cells to the impaired site in the brain after hypoglossal nerve injury Stem Cells. 22 2004 415 427 10.1634/stemcells.22-3-415 15153618 · DOI
  8. [8]Wu G.D. Nolta J.A. Jin Y.S. Barr M.L. Yu H. Starnes V.A. Cramer D.V. Migration of mesenchymal stem cells to heart allografts during chronic rejection Transplantation. 75 2003 679 685 10.1097/01.Tp.0000048488.35010.95 12640309 · DOI
  9. [9]Le Blanc K. Ringdén O. Immunobiology of human mesenchymal stem cells and future use in hematopoietic stem cell transplantation Biol Blood Marrow Transpl. 11 2005 321 334 10.1016/j.bbmt.2005.01.005 15846285 · DOI
  10. [10]Murray I.R. West C.C. Hardy W.R. James A.W. Park T.S. Nguyen A. Tawonsawatruk T. Lazzari L. Soo C. Péault B. Natural history of mesenchymal stem cells, from vessel walls to culture vessels Cell Mol. Life Sci. 71 2014 1353 1374 10.1007/s00018-013-1462-6 24158496 PMC11113613 · DOI
  11. [11]Hasan A. Deeb G. Rahal R. Atwi K. Mondello S. Marei H.E. Gali A. Sleiman E. Mesenchymal stem cells in the treatment of traumatic brain injury Front. Neurol. 8 2017 28 10.3389/fneur.2017.00028 28265255 PMC5316525 · DOI
  12. [12]Bone sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up, Ann Oncol. 23 Suppl 7 (2012) vii100-9. https://doi.org/10.1093/annonc/mds254. 22997441 · DOI
  13. [13]Broadhead M.L. Clark J.C. Myers D.E. Dass C.R. Choong P.F. The molecular pathogenesis of osteosarcoma: a review Sarcoma 2011 2011 959248 10.1155/2011/959248 PMC3087974 21559216 · DOI
  14. [14]Kempf-Bielack B. Bielack S.S. Jürgens H. Branscheid D. Berdel W.E. Exner G.U. Göbel U. Helmke K. Jundt G. Kabisch H. Kevric M. Klingebiel T. Kotz R. Maas R. Schwarz R. Semik M. Treuner J. Zoubek A. Winkler K. Osteosarcoma relapse after combined modality therapy: an analysis of unselected patients in the Cooperative Osteosarcoma Study Group (COSS) J. Clin. Oncol. 23 2005 559 568 10.1200/jco.2005.04.063 15659502 · DOI · Paper page
  15. [15]Sun Z. Wang S. Zhao R.C. The roles of mesenchymal stem cells in tumor inflammatory microenvironment J. Hematol. Oncol. 7 2014 14 10.1186/1756-8722-7-14 24502410 PMC3943443 · DOI · Paper page
  16. [16]Zheng Y. Wang G. Chen R. Hua Y. Cai Z. Mesenchymal stem cells in the osteosarcoma microenvironment: their biological properties, influence on tumor growth, and therapeutic implications Stem Cell Res. Ther. 9 2018 22 10.1186/s13287-018-0780-x 29386041 PMC5793392 · DOI · Paper page
  17. [17]Shimizu T. Ishikawa T. Sugihara E. Kuninaka S. Miyamoto T. Mabuchi Y. Matsuzaki Y. Tsunoda T. Miya F. Morioka H. Nakayama R. Kobayashi E. Toyama Y. Kawai A. Ichikawa H. Hasegawa T. Okada S. Ito T. Ikeda Y. Suda T. Saya H. c-MYC overexpression with loss of Ink4a/Arf transforms bone marrow stromal cells into osteosarcoma accompanied by loss of adipogenesis Oncogene. 29 2010 5687 5699 10.1038/onc.2010.312 20676132 · DOI
  18. [18]A.B. Mohseny, K. Szuhai, S. Romeo, E.P. Buddingh, I. Briaire-de Bruijn, D. de Jong, M. van Pel, A.M. Cleton-Jansen, P.C. Hogendoorn, Osteosarcoma originates from mesenchymal stem cells in consequence of aneuploidization and genomic loss of Cdkn2, J Pathol. 219 (2009) 294–305. DOI:10.1002/path.2603. 19718709 · DOI
  19. [19]Walkley C.R. Qudsi R. Sankaran V.G. Perry J.A. Gostissa M. Roth S.I. Rodda S.J. Snay E. Dunning P. Fahey F.H. Alt F.W. McMahon A.P. Orkin S.H. Conditional mouse osteosarcoma, dependent on p53 loss and potentiated by loss of Rb, mimics the human disease Genes Dev. 22 2008 1662 1676 10.1101/gad.1656808 18559481 PMC2428063 · DOI
  20. [20]Rubio R. Gutierrez-Aranda I. Sáez-Castillo A.I. Labarga A. Rosu-Myles M. Gonzalez-Garcia S. Toribio M.L. Menendez P. Rodriguez R. The differentiation stage of p53-Rb-deficient bone marrow mesenchymal stem cells imposes the phenotype of in vivo sarcoma development Oncogene. 32 2013 4970 4980 10.1038/onc.2012.507 23222711 · DOI
  21. [21]Lin P.P. Pandey M.K. Jin F. Raymond A.K. Akiyama H. Lozano G. Targeted mutation of p53 and Rb in mesenchymal cells of the limb bud produces sarcomas in mice Carcinogenesis 30 2009 1789 1795 10.1093/carcin/bgp180 19635748 PMC4141195 · DOI
  22. [22]Berman S.D. Calo E. Landman A.S. Danielian P.S. Miller E.S. West J.C. Fonhoue B.D. Caron A. Bronson R. Bouxsein M.L. Mukherjee S. Lees J.A. Metastatic osteosarcoma induced by inactivation of Rb and p53 in the osteoblast lineage Proc. Natl. Acad. Sci. U.S.A. 105 2008 11851 11856 10.1073/pnas.0805462105 18697945 PMC2575280 · DOI
  23. [23]Mutsaers A.J. Ng A.J. Baker E.K. Russell M.R. Chalk A.M. Wall M. Liddicoat B.J. Ho P.W. Slavin J.L. Goradia A. Martin T.J. Purton L.E. Dickins R.A. Walkley C.R. Modeling distinct osteosarcoma subtypes in vivo using Cre:lox and lineage-restricted transgenic shRNA Bone 55 2013 166 178 10.1016/j.bone.2013.02.016 23486187 · DOI
  24. [24]Meurette O. Mehlen P. Notch signaling in the tumor microenvironment Cancer Cell. 34 2018 536 548 10.1016/j.ccell.2018.07.009 30146333 · DOI
  25. [25]Quail D.F. Joyce J.A. Microenvironmental regulation of tumor progression and metastasis Nat. Med. 19 2013 1423 1437 10.1038/nm.3394 24202395 PMC3954707 · DOI · Paper page
  26. [26]Hartmann S. Bhola N.E. Grandis J.R. HGF/met signaling in head and neck cancer: impact on the tumor microenvironment Clin. Cancer Res. 22 2016 4005 4013 10.1158/1078-0432.Ccr-16-0951 27370607 PMC6820346 · DOI
  27. [27]Klemm F. Joyce J.A. Microenvironmental regulation of therapeutic response in cancer Trends Cell Biol. 25 2015 198 213 10.1016/j.tcb.2014.11.006 25540894 PMC5424264 · DOI
  28. [28]Kawano M. Tanaka K. Itonaga I. Iwasaki T. Tsumura H. Interaction between human osteosarcoma and mesenchymal stem cells via an interleukin-8 signaling loop in the tumor microenvironment Cell Commun Signal. 16 2018 13 10.1186/s12964-018-0225-2 29625612 PMC5889532 · DOI
  29. [29]Pelagalli A. Nardelli A. Fontanella R. Zannetti A. Inhibition of AQP1 hampers osteosarcoma and hepatocellular carcinoma progression mediated by bone marrow-derived mesenchymal stem cells Int. J. Mol. Sci. 17 2016 10.3390/ijms17071102 PMC4964478 27409610 · DOI
  30. [30]Zhou H. Zarubin T. Ji Z. Min Z. Zhu W. Downey J.S. Lin S. Han J. Frequency and distribution of AP-1 sites in the human genome DNA Res. 12 2005 139 150 10.1093/dnares/12.2.139 16303745 · DOI
  31. [31]Wang J.Y. Wu P.K. Chen P.C. Lee C.W. Chen W.M. Hung S.C. Generation of osteosarcomas from a combination of Rb silencing and c-Myc overexpression in human mesenchymal stem cells Stem Cells Transl. Med. 6 2017 512 526 10.5966/sctm.2015-0226 28191765 PMC5442803 · DOI
  32. [32]Saalfrank A. Janssen K.P. Ravon M. Flisikowski K. Eser S. Steiger K. Flisikowska T. Müller-Fliedner P. Schulze É. Brönner C. Gnann A. Kappe E. Böhm B. Schade B. Certa U. Saur D. Esposito I. Kind A. Schnieke A. A porcine model of osteosarcoma Oncogenesis 5 2016 e210 10.1038/oncsis.2016.19 PMC4815050 26974205 · DOI
  33. [33]Lin L. Huang K. Guo W. Zhou C. Wang G. Zhao Q. Conditioned medium of the osteosarcoma cell line U2OS induces hBMSCs to exhibit characteristics of carcinoma-associated fibroblasts via activation of IL-6/STAT3 signalling J. Biochem. 168 2020 265 271 10.1093/jb/mvaa044 32302384 · DOI
  34. [34]Zhu H. Guo S. Zhang Y. Yin J. Yin W. Tao S. Wang Y. Zhang C. Proton-sensing GPCR-YAP signalling promotes cancer-associated fibroblast activation of mesenchymal stem cells Int. J. Biol. Sci. 12 2016 389 396 10.7150/ijbs.13688 27019624 PMC4807159 · DOI
  35. [35]Pietrovito L. Leo A. Gori V. Lulli M. Parri M. Becherucci V. Piccini L. Bambi F. Taddei M.L. Chiarugi P. Bone marrow-derived mesenchymal stem cells promote invasiveness and transendothelial migration of osteosarcoma cells via a mesenchymal to amoeboid transition Mol. Oncol. 12 2018 659 676 10.1002/1878-0261.12189 29517849 PMC5928379 · DOI
  36. [36]Wang Y.M. Wang W. Qiu E.D. Osteosarcoma cells induce differentiation of mesenchymal stem cells into cancer associated fibroblasts through Notch and Akt signaling pathway Int. J. Clin. Exp. Pathol. 10 2017 8479 8486 31966700 PMC6965449
  37. [37]Frantz C. Stewart K.M. Weaver V.M. The extracellular matrix at a glance J. Cell Sci. 123 2010 4195 4200 10.1242/jcs.023820 21123617 PMC2995612 · DOI · Paper page
  38. [38]Fu R. Zhang Y.W. Li H.M. Lv W.C. Zhao L. Guo Q.L. Lu T. Weiss S.J. Li Z.Y. Wu Z.Q. LW106, a novel indoleamine 2,3-dioxygenase 1 inhibitor, suppresses tumour progression by limiting stroma-immune crosstalk and cancer stem cell enrichment in tumour micro-environment Br. J. Pharmacol. 175 2018 3034 3049 10.1111/bph.14351 29722898 PMC6016675 · DOI
  39. [39]Walker C. Mojares E. Del Río Hernández A. Role of extracellular matrix in development and cancer progression Int. J. Mol. Sci. 19 2018 10.3390/ijms19103028 PMC6213383 30287763 · DOI
  40. [40]Cai R. Kawazoe N. Chen G. Influence of surfaces modified with biomimetic extracellular matrices on adhesion and proliferation of mesenchymal stem cells and osteosarcoma cells Colloids Surf. B Biointerfaces. 126 2015 381 386 10.1016/j.colsurfb.2014.11.050 25516267 · DOI
  41. [41]Halpern J.L. Kilbarger A. Lynch C.C. Mesenchymal stem cells promote mammary cancer cell migration in vitro via the CXCR2 receptor Cancer Lett. 308 2011 91 99 10.1016/j.canlet.2011.04.018 21601983 PMC3311035 · DOI
  42. [42]Li Y.J. Dai Y.L. Zhang W.B. Li S.J. Tu C.Q. Clinicopathological and prognostic significance of chemokine receptor CXCR4 in patients with bone and soft tissue sarcoma: a meta-analysis Clin. Exp. Med. 17 2017 59 69 10.1007/s10238-015-0405-y 26678086 · DOI
  43. [43]Y. Han, C. Wu, J. Wang, N. Liu, CXCR7 maintains osteosarcoma invasion after CXCR4 suppression in bone marrow microenvironment, Tumour Biol. 39 (2017) 1010428317701631. DOI:10.1177/1010428317701631. 28468584 · DOI
  44. [45]Walter M. Liang S. Ghosh S. Hornsby P.J. Li R. Interleukin 6 secreted from adipose stromal cells promotes migration and invasion of breast cancer cells Oncogene. 28 2009 2745 2755 10.1038/onc.2009.130 19483720 PMC2806057 · DOI · Paper page
  45. [46]Avnet S. Longhi A. Salerno M. Halleen J.M. Perut F. Granchi D. Ferrari S. Bertoni F. Giunti A. Baldini N. Increased osteoclast activity is associated with aggressiveness of osteosarcoma Int. J. Oncol. 33 2008 1231 1238 19020756
  46. [47]Duan Z. Lamendola D.E. Penson R.T. Kronish K.M. Seiden M.V. Overexpression of IL-6 but not IL-8 increases paclitaxel resistance of U-2OS human osteosarcoma cells Cytokine 17 2002 234 242 10.1006/cyto.2001.1008 12027404 · DOI
  47. [49]Sedlakova O. Svastova E. Takacova M. Kopacek J. Pastorek J. Pastorekova S. Carbonic anhydrase IX, a hypoxia-induced catalytic component of the pH regulating machinery in tumors Front. Physiol. 4 2014 400 10.3389/fphys.2013.00400 24409151 PMC3884196 · DOI
  48. [50]Avnet S. Di Pompo G. Chano T. Errani C. Ibrahim-Hashim A. Gillies R.J. Donati D.M. Baldini N. Cancer-associated mesenchymal stroma fosters the stemness of osteosarcoma cells in response to intratumoral acidosis via NF-κB activation Int. J. Cancer 140 2017 1331 1345 10.1002/ijc.30540 27888521 PMC5272857 · DOI
  49. [51]Chou A.J. Geller D.S. Gorlick R. Therapy for osteosarcoma: where do we go from here? Paediatr Drugs 10 2008 315 327 10.2165/00148581-200810050-00005 18754698 · DOI
  50. [52]Yu F.X. Hu W.J. He B. Zheng Y.H. Zhang Q.Y. Chen L. Bone marrow mesenchymal stem cells promote osteosarcoma cell proliferation and invasion World J. Surg. Oncol. 13 2015 52 10.1186/s12957-015-0465-1 25890096 PMC4334855 · DOI
  51. [53]Colombo M. Raposo G. Théry C. Biogenesis, secretion, and intercellular interactions of exosomes and other extracellular vesicles Annu. Rev. Cell Dev. Biol. 30 2014 255 289 10.1146/annurev-cellbio-101512-122326 25288114 · DOI · Paper page
  52. [54]Perut F. Roncuzzi L. Baldini N. The emerging roles of extracellular vesicles in osteosarcoma Front. Oncol. 9 2019 1342 10.3389/fonc.2019.01342 31850225 PMC6901498 · DOI
  53. [55]Shao H. Im H. Castro C.M. Breakefield X. Weissleder R. Lee H. New technologies for analysis of extracellular vesicles Chem. Rev. 118 2018 1917 1950 10.1021/acs.chemrev.7b00534 29384376 PMC6029891 · DOI
  54. [56]Zhuang G. Wu X. Jiang Z. Kasman I. Yao J. Guan Y. Oeh J. Modrusan Z. Bais C. Sampath D. Ferrara N. Tumour-secreted miR-9 promotes endothelial cell migration and angiogenesis by activating the JAK-STAT pathway Embo J. 31 2012 3513 3523 10.1038/emboj.2012.183 22773185 PMC3433782 · DOI
  55. [57]Chalmin F. Ladoire S. Mignot G. Vincent J. Bruchard M. Remy-Martin J.P. Boireau W. Rouleau A. Simon B. Lanneau D. De Thonel A. Multhoff G. Hamman A. Martin F. Chauffert B. Solary E. Zitvogel L. Garrido C. Ryffel B. Borg C. Apetoh L. Rébé C. Ghiringhelli F. Membrane-associated Hsp72 from tumor-derived exosomes mediates STAT3-dependent immunosuppressive function of mouse and human myeloid-derived suppressor cells J. Clin. Invest. 120 2010 457 471 10.1172/jci40483 20093776 PMC2810085 · DOI
  56. [58]Mannerström B. Kornilov R. Abu-Shahba A.G. Chowdhury I.M. Sinha S. Seppänen-Kaijansinkko R. Kaur S. Epigenetic alterations in mesenchymal stem cells by osteosarcoma-derived extracellular vesicles Epigenetics 14 2019 352 364 10.1080/15592294.2019.1585177 30907225 PMC6557543 · DOI
  57. [59]Vallabhaneni K.C. Hassler M.Y. Abraham A. Whitt J. Mo Y.Y. Atfi A. Pochampally R. Mesenchymal stem/stromal cells under stress increase osteosarcoma migration and apoptosis resistance via extracellular vesicle mediated communication PLoS One. 11 2016 e0166027 10.1371/journal.pone.0166027 PMC5094708 27812189 · DOI
  58. [60]Baglio S.R. Lagerweij T. Pérez-Lanzón M. Ho X.D. Léveillé N. Melo S.A. Cleton-Jansen A.M. Jordanova E.S. Roncuzzi L. Greco M. van Eijndhoven M.A.J. Grisendi G. Dominici M. Bonafede R. Lougheed S.M. de Gruijl T.D. Zini N. Cervo S. Steffan A. Canzonieri V. Martson A. Maasalu K. Köks S. Wurdinger T. Baldini N. Pegtel D.M. Blocking tumor-educated MSC paracrine activity halts osteosarcoma progression Clin. Cancer Res. 23 2017 3721 3733 10.1158/1078-0432.Ccr-16-2726 28053020 · DOI · Paper page
  59. [61]Lagerweij T. Pérez-Lanzón M. Baglio S.R. A preclinical mouse model of osteosarcoma to define the extracellular vesicle-mediated communication between tumor and mesenchymal stem cells J. Vis. Exp. 2018 10.3791/56932 PMC6101124 29782011 · DOI
  60. [62]Semenza G.L. Molecular mechanisms mediating metastasis of hypoxic breast cancer cells Trends Mol. Med. 18 2012 534 543 10.1016/j.molmed.2012.08.001 22921864 PMC3449282 · DOI
  61. [64]Lin S. Zhu B. Huang G. Zeng Q. Wang C. Microvesicles derived from human bone marrow mesenchymal stem cells promote U2OS cell growth under hypoxia: the role of PI3K/AKT and HIF-1α Hum. Cell 32 2019 64 74 10.1007/s13577-018-0224-z 30506278 · DOI
  62. [65]Milane L. Singh A. Mattheolabakis G. Suresh M. Amiji M.M. Exosome mediated communication within the tumor microenvironment J. Control Release. 219 2015 278 294 10.1016/j.jconrel.2015.06.029 26143224 · DOI
  63. [66]Mathieu M. Martin-Jaular L. Lavieu G. Théry C. Specificities of secretion and uptake of exosomes and other extracellular vesicles for cell-to-cell communication Nat. Cell Biol. 21 2019 9 17 10.1038/s41556-018-0250-9 30602770 · DOI
  64. [67]Yu B. Zhang X. Li X. Exosomes derived from mesenchymal stem cells Int. J. Mol. Sci. 15 2014 4142 4157 10.3390/ijms15034142 24608926 PMC3975389 · DOI
  65. [68]Nawaz M. Fatima F. Vallabhaneni K.C. Penfornis P. Valadi H. Ekström K. Kholia S. Whitt J.D. Fernandes J.D. Pochampally R. Squire J.A. Camussi G. Extracellular vesicles: evolving factors in stem cell biology Stem Cells Int. 2016 2016 1073140 10.1155/2016/1073140 26649044 PMC4663346 · DOI
  66. [69]Kidd S. Spaeth E. Dembinski J.L. Dietrich M. Watson K. Klopp A. Battula V.L. Weil M. Andreeff M. Marini F.C. Direct evidence of mesenchymal stem cell tropism for tumor and wounding microenvironments using in vivo bioluminescent imaging Stem Cells. 27 2009 2614 2623 10.1002/stem.187 19650040 PMC4160730 · DOI
  67. [70]Huang Y. Liu W. He B. Wang L. Zhang F. Shu H. Sun L. Exosomes derived from bone marrow mesenchymal stem cells promote osteosarcoma development by activating oncogenic autophagy J. Bone Oncol. 21 2020 100280 10.1016/j.jbo.2020.100280 PMC7019122 32082984 · DOI · Paper page
  68. [71]Sun Z. Shi K. Yang S. Liu J. Zhou Q. Wang G. Song J. Li Z. Zhang Z. Yuan W. Effect of exosomal miRNA on cancer biology and clinical applications Mol. Cancer. 17 2018 147 10.1186/s12943-018-0897-7 30309355 PMC6182840 · DOI · Paper page
  69. [73]Kinoshita T. Yip K.W. Spence T. Liu F.F. MicroRNAs in extracellular vesicles: potential cancer biomarkers J. Hum. Genet. 62 2017 67 74 10.1038/jhg.2016.87 27383658 · DOI
  70. [74]Qin F. Tang H. Zhang Y. Zhang Z. Huang P. Zhu J. Bone marrow-derived mesenchymal stem cell-derived exosomal microRNA-208a promotes osteosarcoma cell proliferation, migration, and invasion J. Cell Physiol. 235 2020 4734 4745 10.1002/jcp.29351 31637737 · DOI
  71. [75]Zhang H. Wang J. Ren T. Huang Y. Liang X. Yu Y. Wang W. Niu J. Guo W. Bone marrow mesenchymal stem cell-derived exosomal miR-206 inhibits osteosarcoma progression by targeting TRA2B Cancer Lett. 490 2020 54 65 10.1016/j.canlet.2020.07.008 32682951 · DOI
  72. [77]Hennet T. Collagen glycosylation Curr. Opin. Struct. Biol. 56 2019 131 138 10.1016/j.sbi.2019.01.015 30822656 · DOI
  73. [78]Wang Y. Chu Y. Li K. Zhang G. Guo Z. Wu X. Qiu C. Li Y. Wan X. Sui J. Zhang D. Xiang H. Chen B. Exosomes secreted by adipose-derived mesenchymal stem cells foster metastasis and osteosarcoma proliferation by increasing COLGALT2 expression Front. Cell Dev. Biol. 8 2020 353 10.3389/fcell.2020.00353 32523950 PMC7262406 · DOI
  74. [79]Deng T. Lyon C.J. Bergin S. Caligiuri M.A. Hsueh W.A. Obesity, inflammation, and cancer Annu. Rev. Pathol. 11 2016 421 449 10.1146/annurev-pathol-012615-044359 27193454 · DOI
  75. [80]Aanstoos M.E. Regan D.P. Rose R.J. Chubb L.S. Ehrhart N.P. Do mesenchymal stromal cells influence microscopic residual or metastatic osteosarcoma in a murine model? Clin. Orthop Relat. Res. 474 2016 707 715 10.1007/s11999-015-4362-2 26018200 PMC4746149 · DOI · Paper page
  76. [83]NguyenThai Q.A. Sharma N. Luong do H. Sodhi S.S. Kim J.H. Kim N. Oh S.J. Jeong D.K. Targeted inhibition of osteosarcoma tumor growth by bone marrow-derived mesenchymal stem cells expressing cytosine deaminase/5-fluorocytosine in tumor-bearing mice J. Gene Med. 17 2015 87 99 10.1002/jgm.2826 25808408 · DOI · Paper page
  77. [84]Paino F. La Noce M. Di Nucci D. Nicoletti G.F. Salzillo R. De Rosa A. Ferraro G.A. Papaccio G. Desiderio V. Tirino V. Human adipose stem cell differentiation is highly affected by cancer cells both in vitro and in vivo: implication for autologous fat grafting Cell Death Dis. 8 2017 e2568 10.1038/cddis.2016.308 PMC5386348 28102844 · DOI
  78. [85]Shen W.C. Lai Y.C. Li L.H. Liao K. Lai H.C. Kao S.Y. Wang J. Chuong C.M. Hung S.C. Methylation and PTEN activation in dental pulp mesenchymal stem cells promotes osteogenesis and reduces oncogenesis Nat. Commun. 10 2019 2226 10.1038/s41467-019-10197-x 31110221 PMC6527698 · DOI
  79. [86]De Becker A. Riet I.V. Homing and migration of mesenchymal stromal cells: How to improve the efficacy of cell therapy? World J. Stem Cells. 8 2016 73 87 10.4252/wjsc.v8.i3.73 27022438 PMC4807311 · DOI
  80. [87]Nitzsche F. Müller C. Lukomska B. Jolkkonen J. Deten A. Boltze J. Concise review: MSC adhesion cascade-insights into homing and transendothelial migration Stem Cells. 35 2017 1446 1460 10.1002/stem.2614 28316123 · DOI
  81. [88]Tat S.K. Padrines M. Theoleyre S. Couillaud-Battaglia S. Heymann D. Redini F. Fortun Y. OPG/membranous–RANKL complex is internalized via the clathrin pathway before a lysosomal and a proteasomal degradation Bone. 39 2006 706 715 10.1016/j.bone.2006.03.016 16750945 · DOI · Paper page
  82. [91]Sage E.K. Kolluri K.K. McNulty K. Lourenco Sda S. Kalber T.L. Ordidge K.L. Davies D. Gary Lee Y.C. Giangreco A. Janes S.M. Systemic but not topical TRAIL-expressing mesenchymal stem cells reduce tumour growth in malignant mesothelioma Thorax 69 2014 638 647 10.1136/thoraxjnl-2013-204110 24567297 PMC4078753 · DOI
  83. [92]Kanehira M. Xin H. Hoshino K. Maemondo M. Mizuguchi H. Hayakawa T. Matsumoto K. Nakamura T. Nukiwa T. Saijo Y. Targeted delivery of NK4 to multiple lung tumors by bone marrow-derived mesenchymal stem cells Cancer Gene Ther. 14 2007 894 903 10.1038/sj.cgt.7701079 17693990 · DOI
  84. [93]Sasportas L.S. Kasmieh R. Wakimoto H. Hingtgen S. van de Water J.A. Mohapatra G. Figueiredo J.L. Martuza R.L. Weissleder R. Shah K. Assessment of therapeutic efficacy and fate of engineered human mesenchymal stem cells for cancer therapy Proc. Natl. Acad. Sci. U.S.A. 106 2009 4822 4827 10.1073/pnas.0806647106 19264968 PMC2660771 · DOI
  85. [94]Tyciakova S. Matuskova M. Bohovic R. Polakova K. Toro L. Skolekova S. Kucerova L. Genetically engineered mesenchymal stromal cells producing TNFα have tumour suppressing effect on human melanoma xenograft J. Gene Med. 17 2015 54 67 10.1002/jgm.2823 25677845 · DOI
  86. [95]Choi S.H. Tamura K. Khajuria R.K. Bhere D. Nesterenko I. Lawler J. Shah K. Antiangiogenic variant of TSP-1 targets tumor cells in glioblastomas Mol. Ther. 23 2015 235 243 10.1038/mt.2014.214 25358253 PMC4445617 · DOI
  87. [97]Martínez-González I. Roca O. Masclans J.R. Moreno R. Salcedo M.T. Baekelandt V. Cruz M.J. Rello J. Aran J.M. Human mesenchymal stem cells overexpressing the IL-33 antagonist soluble IL-1 receptor-like-1 attenuate endotoxin-induced acute lung injury Am. J. Respir. Cell Mol. Biol. 49 2013 552 562 10.1165/rcmb.2012-0406OC 23656573 · DOI
  88. [98]Niu J. Yue W. Song Y. Zhang Y. Qi X. Wang Z. Liu B. Shen H. Hu X. Prevention of acute liver allograft rejection by IL-10-engineered mesenchymal stem cells Clin. Exp. Immunol. 176 2014 473 484 10.1111/cei.12283 24527865 PMC4008992 · DOI
  89. [99]Pessina A. Bonomi A. Coccè V. Invernici G. Navone S. Cavicchini L. Sisto F. Ferrari M. Viganò L. Locatelli A. Ciusani E. Cappelletti G. Cartelli D. Arnaldo C. Parati E. Marfia G. Pallini R. Falchetti M.L. Alessandri G. Mesenchymal stromal cells primed with paclitaxel provide a new approach for cancer therapy PLoS One 6 2011 e28321 10.1371/journal.pone.0028321 PMC3243689 22205945 · DOI
  90. [100]Krueger T.E.G. Thorek D.L.J. Denmeade S.R. Isaacs J.T. Brennen W.N. Concise review: mesenchymal stem cell-based drug delivery: the good, the bad, the ugly, and the promise Stem Cells Transl. Med. 7 2018 651 663 10.1002/sctm.18-0024 30070053 PMC6127224 · DOI
  91. [101]Baek G. Choi H. Kim Y. Lee H.C. Choi C. Mesenchymal stem cell-derived extracellular vesicles as therapeutics and as a drug delivery platform Stem Cells Transl. Med. 8 2019 880 886 10.1002/sctm.18-0226 31045328 PMC6708072 · DOI
  92. [102]Marote A. Teixeira F.G. Mendes-Pinheiro B. Salgado A.J. MSCs-derived exosomes: cell-secreted nanovesicles with regenerative potential Front. Pharmacol. 7 2016 231 10.3389/fphar.2016.00231 27536241 PMC4971062 · DOI
  93. [103]Abello J. Nguyen T.D.T. Marasini R. Aryal S. Weiss M.L. Biodistribution of gadolinium- and near infrared-labeled human umbilical cord mesenchymal stromal cell-derived exosomes in tumor bearing mice Theranostics 9 2019 2325 2345 10.7150/thno.30030 31149047 PMC6531310 · DOI
  94. [104]Munagala R. Aqil F. Jeyabalan J. Agrawal A.K. Mudd A.M. Kyakulaga A.H. Singh I.P. Vadhanam M.V. Gupta R.C. Exosomal formulation of anthocyanidins against multiple cancer types Cancer Lett. 393 2017 94 102 10.1016/j.canlet.2017.02.004 28202351 PMC5837866 · DOI
  95. [105]Morishita M. Takahashi Y. Nishikawa M. Ariizumi R. Takakura Y. Enhanced Class I tumor antigen presentation via cytosolic delivery of exosomal cargos by tumor-cell-derived exosomes displaying a pH-sensitive fusogenic peptide Mol. Pharm. 14 2017 4079 4086 10.1021/acs.molpharmaceut.7b00760 28977747 · DOI
  96. [106]Hadla M. Palazzolo S. Corona G. Caligiuri I. Canzonieri V. Toffoli G. Rizzolio F. Exosomes increase the therapeutic index of doxorubicin in breast and ovarian cancer mouse models Nanomedicine (Lond) 11 2016 2431 2441 10.2217/nnm-2016-0154 27558906 · DOI
  97. [107]Li Y. Gao Y. Gong C. Wang Z. Xia Q. Gu F. Hu C. Zhang L. Guo H. Gao S. A33 antibody-functionalized exosomes for targeted delivery of doxorubicin against colorectal cancer Nanomedicine 14 2018 1973 1985 10.1016/j.nano.2018.05.020 29935333 · DOI
  98. [108]Li H. Yang C. Shi Y. Zhao L. Exosomes derived from siRNA against GRP78 modified bone-marrow-derived mesenchymal stem cells suppress Sorafenib resistance in hepatocellular carcinoma J. Nanobiotechnol. 16 2018 103 10.1186/s12951-018-0429-z PMC6300915 30572882 · DOI
  99. [109]Altanerova U. Jakubechova J. Benejova K. Priscakova P. Repiska V. Babelova A. Smolkova B. Altaner C. Intracellular prodrug gene therapy for cancer mediated by tumor cell suicide gene exosomes Int. J. Cancer. 148 2021 128 139 10.1002/ijc.33188 32621791 · DOI
  100. [110]Mosallaei M. Simonian M. Ehtesham N. Karimzadeh M.R. Vatandoost N. Negahdari B. Salehi R. Genetically engineered mesenchymal stem cells: targeted delivery of immunomodulatory agents for tumor eradication Cancer Gene Ther. 2020 10.1038/s41417-020-0179-6 32418986 · DOI
  101. [111]Poggi A. Varesano S. Zocchi M.R. How to hit mesenchymal stromal cells and make the tumor microenvironment immunostimulant rather than immunosuppressive Front. Immunol. 2018 10.3389/fimmu.2018.00262 PMC5825917 29515580 · DOI
  102. [112]Razmkhah M. Abtahi S. Ghaderi A. Mesenchymal stem cells, immune cells and tumor cells crosstalk: a sinister triangle in the tumor microenvironment Curr Stem Cell Res. Ther. 2019 10.2174/1574888X13666180816114809 30112998 · DOI
  103. [113]Sineh Sepehr K. Razavi A. Hassan Z.M. Fazel A. Abdollahpour-Alitappeh M. Mossahebi-Mohammadi M. Yekaninejad M.S. Farhadihosseinabadi B. Hashemi S.M. Comparative immunomodulatory properties of mesenchymal stem cells derived from human breast tumor and normal breast adipose tissue Cancer Immunol. Immunother. 2020 10.1007/s00262-020-02567-y PMC11027656 32350594 · DOI
  104. [114]Hernigou P. Mathieu G. Poignard A. Manicom O. Beaujean F. Rouard H. Percutaneous autologous bone-marrow grafting for nonunions. Surgical technique J. Bone Joint Surg. Am. 2006 10.2106/JBJS.F.00203 16951103 · DOI
  105. [115]Hernigou P. Guissou I. Homma Y. Poignard A. Chevallier N. Rouard H. Flouzat Lachaniette C.H. Percutaneous injection of bone marrow mesenchymal stem cells for ankle non-unions decreases complications in patients with diabetes Int. Orthop. 2015 10.1007/s00264-015-2738-2 25795249 · DOI · Paper page
  106. [116]P. Douras, T. Tosounidis, P.V. Giannoudis. Application of the 'diamond concept' with fast bone marrow aspirate concentration for the treatment of medial malleolus non-union Injury. 2018 DOI:10.1016/j.injury.2018.11.013. 30526927 · DOI
  107. [117]Hernigou P. Trousselier M. Roubineau F. Bouthors C. Chevallier N. Rouard H. Flouzat-Lachaniette C.H. Stem cell therapy for the treatment of hip osteonecrosis: a 30-year review of progress Clin. Orthop Surg. 2016 10.4055/cios.2016.8.1 PMC4761591 26929793 · DOI

Cited by

Sorted by citations

Authors
Chang, X., Ma, Z., Zhu, G., Lu, Y., & Yang, J.
Affiliations
Lanzhou University (CN)
Corresponding author
Yang, Jingjing
ORCID
Venue
Journal of Bone Oncology
Publisher
Elsevier BV
Published
2021-08
Volume
29
Pages
100372
ISSN
  • 2212-1366 (ISSN-L)
  • 2212-1374
DOI
10.1016/j.jbo.2021.100372
PMC
PMC8254115
OpenAlex
W3174085197
Cited by
70
References
9
Citations by year
2026: 5 · 2025: 15 · 2024: 13 · 2023: 18 · 2022: 15 · 2021: 4
FWCI
1.78
Type
journal article
Language
en
Open access
Licence
Locations
  • Journal of bone oncology (publishedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
  • Lanzhou University Institutional Repository (submittedVersion, cc-by-nc-nd)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • Lanzhou University
  • Gansu Province Science and Technology Department (GZK-2019-46)
Topics
  • Health Sciences › Medicine › Genetics › Mesenchymal stem cell research
  • Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Sarcoma Diagnosis and Treatment
Keywords
mesenchymal stem cells, osteosarcoma, tumor microenvironment, extracellular vesicles, paracrine signaling, autocrine signaling, gene therapy, targeted cancer therapy, carcinogenesis

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review